ArticleFrontiers in immunology2025
Pharmacological inhibition of the RhoA pathway by melatonin reduces viral replication and proinflammatory response against ZIKV and DENV-4 neuroinfections.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Zika virus (ZIKV) and dengue virus (DENV) are mosquito-borne flaviviruses associated with serious neurological complications, such as Guillain-Barré syndrome and congenital Zika syndrome (ZIKV), as well as encephalitis, meningitis, and stroke (DENV). Despite their growing public health impact in tropical regions, there are currently no specific treatments available. Both viruses modulate the RhoA GTPase pathway, which is involved in immune regulation and cytoskeletal dynamics. Melatonin, a hormone with antioxidant and immunomodulatory properties, has previously been shown to inhibit Japanese encephalitis virus (JEV) replication through RhoA pathway modulation. Methods: We evaluated the antiviral potential of melatonin against ZIKV and DENV-4 in vitro using U87-MG cells and in vivo using two mouse models: immunodeficient AG129 and neonatal immunocompetent CD1 mice. Antiviral and immunomodulatory effects were assessed by quantitative RT-PCR and analysis of inflammatory markers, including interferon-stimulated genes (MX1, IFI44L, IFN-β) and cytokines (IL-1β, TNF-α). Microglial activation and polarization were also analyzed in brain tissues. Results: Melatonin treatment significantly reduced ZIKV and DENV-4 replication and the associated inflammatory response in U87-MG cells. In AG129 mice, melatonin increased survival, attenuated clinical signs during DENV-4 infection, and reduced viral genome copies of both viruses. In neonatal CD1 mice, melatonin markedly decreased viral loads in the brain and suppressed inflammatory gene expression, microglial activation, and M1/M2 polarization imbalance. Discussion: Our findings demonstrate that melatonin exerts both antiviral and anti-inflammatory effects against ZIKV and DENV-4 infections in vitro and in vivo, likely through inhibition of the RhoA signaling pathway. These results suggest that melatonin is a promising therapeutic candidate for neuroinfections caused by flaviviruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.